Emcutix Biopharmaceuticals Ltd., a subsidiary of Emcure Pharmaceuticals, has entered the anti-acne skincare market with the launch of its Flawlizo Xpert Acne Care range—offering targeted, science-led solutions for fast and effective acne management.
The highlight of the consumer range includes:
-
Flawlizo Acne Spot Corrector – a biphasic formulation clinically proven to reduce early breakouts within 3–5 days
-
Flawlizo Acne Care Moisturizing Gel – a non-comedogenic, hydrating solution enriched with natural extracts, designed to nourish acne-prone skin without clogging pores
The products are developed to deliver visible results, while maintaining skin barrier integrity and hydration—offering a complete acne care routine that addresses breakout treatment and long-term skin health.
In addition to the consumer offerings, the Flawlizo portfolio also includes five prescription-only products featuring Tretinoin, a globally recognized gold-standard acne treatment. These are manufactured at Encube Ethicals, a USFDA-certified facility with one of the largest global capabilities in topical dermatological formulations.
Sathya Narayanan, CEO, Emcutix Biopharmaceuticals Ltd., stated:
“Flawlizo reflects our commitment to uniting clinical science with real-world skincare needs. It empowers individuals to manage acne with confidence and care, using safe, effective, and accessible solutions.”
This launch reinforces Emcutix’s growing footprint in dermatology, spanning prescription, aesthetic, and over-the-counter skincare solutions. The move follows the company’s exclusive licensing partnership with WiQo, introducing PRX-PLUS, a non-invasive skin treatment, to the Indian market for the first time.
